NVCT

Latest SEC Filings & News for NVCT

2 most recent filings and news items mentioning NVCT. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/NVCT/news?limit=20"

Pull NVCT filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

OfferingAug 4, 2026Neutral

Nuvectis in-licenses late-stage oncology drugs and raises $115M in follow-on offering to fund pipeline expansion

Nuvectis acquired ex-China rights to oncology assets NXP100 and NXP200 and closed a $115M July 2026 follow-on offering with cash runway extending into 1H 2029.

View filing at SEC.gov →

M&AJun 23, 2026Positive

Nuvectis Agrees to License Drug Assets from Haisco

Nuvectis Pharma expands its pipeline by licensing ex-China rights for NXP100 and NXP200 from Haisco Pharmaceutical Group. This strategic acquisition of two clinical-stage assets aims to strengthen the company's focus on complement-mediated diseases and oncology.

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.